CoChat

The DOI matches its Crossref record; the references it cites are not checked yet.

Control of fibrosis with enhanced safety via asymmetric inhibition of prolyl‐tRNA synthetase 1

Open access
Yoon, Ina, Kim, Sulhee, Cho, Minjae, You, Kyung Ah, Son, Jonghyeon, Lee, Caroline, Suh, Ji Hun, Bae, Da‐Jeong, Kim, Jong Min, Oh, Sinae, Park, Songhwa, Kim, Sanga, Cho, Seong Hyeok, Park, Seonha, Bang, Kyuhyeon, Seo, Minjeong, Kim, Jong Hyun, Lee, Bongyong, Park, Joon Seok, Hwang, Kwang Yeon, Kim, Sunghoon · 2023 · EMBO Molecular Medicine

Abstract

Prolyl‐tRNA synthetase 1 (PARS1) has attracted much interest in controlling pathologic accumulation of collagen containing high amounts of proline in fibrotic diseases. However, there are concerns about its catalytic inhibition for potential adverse effects on global protein synthesis. We developed a novel compound, DWN12088, whose safety was validated by clinical phase 1 studies, and therapeutic efficacy was shown in idiopathic pulmonary fibrosis model. Structural and kinetic analyses revealed that DWN12088 binds to catalytic site of each protomer of PARS1 dimer in an asymmetric mode with different affinity, resulting in decreased responsiveness at higher doses, thereby expanding safety window. The mutations disrupting PARS1 homodimerization restored the sensitivity to DWN12088, validating negative communication between PARS1 promoters for the DWN12088 binding. Thus, this work suggests that DWN12088, an asymmetric catalytic inhibitor of PARS1 as a novel therapeutic agent against fibrosis with enhanced safety.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.15252/emmm.202216940

Cites

Statistics

Figures

Figure EV1 Significance of EPRS1 for cellular collagen synthesis A WI‐26 VA4 cells were made to stably express Flag‐EPRS1 in the presence of doxycycline (WI‐26 VA4Flag‐EPRS1 stable cells). The cells were transfected with negative control or untranslated region (UTR) of EPRS1‐targeting siRNAs for 72 h. The cells were also incubated in the presence of doxycycline for 68 h. After starved of serum for 6 h, the cells were treated with TGF‐β for 15 h. The level of COL1A1 was determined by immunoblot assay. The level of β‐actin was used as loading control.B, C WI‐26 VA4 cells were transfected with the indicated siRNAs for 72 h and incubated with TGF‐β for 15 h. The level of COL1A1 was determined by immunoblot assay.D The proportion of proline and the half‐lives of proteins detected in (B) and (C) are listed in the table. The proportion of proline in the polypeptide sequence was calculated based on UniProtKB. The half‐lives of proteins were cited from a study that measured half‐lives of whole proteome in NIH3T3 cells via mass spectrometry (Schwanhausser et al, 2011). Source data are available online for this figure.
Figure EV1 Significance of EPRS1 for cellular collagen synthesis A WI‐26 VA4 cells were made to stably express Flag‐EPRS1 in the presence of doxycycline (WI‐26 VA4Flag‐EPRS1 stable cells). The cells were transfected with negative control or untranslated region (UTR) of EPRS1‐targeting siRNAs for 72 h. The cells were also incubated in the presence of doxycycline for 68 h. After starved of serum for 6 h, the cells were treated with TGF‐β for 15 h. The level of COL1A1 was determined by immunoblot assay. The level of β‐actin was used as loading control.B, C WI‐26 VA4 cells were transfected with the indicated siRNAs for 72 h and incubated with TGF‐β for 15 h. The level of COL1A1 was determined by immunoblot assay.D The proportion of proline and the half‐lives of proteins detected in (B) and (C) are listed in the table. The proportion of proline in the polypeptide sequence was calculated based on UniProtKB. The half‐lives of proteins were cited from a study that measured half‐lives of whole proteome in NIH3T3 cells via mass spectrometry (Schwanhausser et al, 2011). Source data are available online for this figure.CC BY · PubMed Central
Figure 1 Identification and characterization of DWN12088 with higher safety compared with HF A A total 523 HF derivatives were tested for in vitro efficacy, intracellular efficacy, cytotoxicity, in vivo efficacy, and in vivo toxicity as described in the Methods section. DWN12088 was selected as the final candidate. At each step, the compounds that met each screening criteria are shown in pink lines. The detailed screening strategy is described in Fig EV2.B Dose–response curve of HF and DWN12088 in WI‐26 VA4 cells. The IC50 value for collagen level was measured as a representative of chemical efficacy. The cells were starved of serum for 6 h and then incubated with the indicated concentrations of compounds in the presence of TGF‐β (2 ng/ml) for 72 h. The secreted pro‐collagen I levels were determined by ELISA. The CC50 values were determined by CellTiter‐Glo assay. Dose–response curves were determined by combining at least two biologically independent experiments. The IC50 values were calculated using GraphPad Prism 7.0 (Collagen level, n = 5 from three independent experiments (singlicate for one experiment and duplicate for two experiments; mean ± SEM); Celltiter‐Glo assay, n = 4 from two independent experiments (duplicate for each experiment; mean ± SEM).C The TI of HF and DWN12088 was determined by dividing the CC50 with the IC50 for collagen level (Welch's t test; ***P < 0.001; mean ± SEM).D Schedules of two different in vivo efficacy tests.E–I In vivo efficacy of HF and DWN12088 was determined in a bleomycin‐induced lung fibrosis model. The indicated concentrations of HF or DWN12088 were orally administered to mice once a day for 2 weeks from a week after intratracheal injection of bleomycin (D, model 1). The saturation of percutaneous oxygen (SpO2) (E) was determined as a measurement of lung function. The number of cells in bronchoalveolar lavage fluid (BALF) was counted as a measure of inflammation response (F). The collagen level was determined by hydroxyproline assay (G) and Masson's trichrome staining (H and I) of lung tissues. The remaining Masson's trichrome staining images shown in Fig 1I are presented in Appendix Fig S2 (n = 5; Mann–Whitney test after Kruskal–Wallis test; *P < 0.05, **P < 0.01; mean ± SEM). scale bar = 200 μm. BLM, bleomycin; PO, per oral; QD, once a day; 12088, DWN12088; HF (0.05), HF 0.05 mg/kg; HF (0.1), HF 0.1 mg/kg; DWN12088 (10), DWN12088 10 mg/kg; b, bronchiole; v, blood vessel. Source data are available online for this figure.
Figure 1 Identification and characterization of DWN12088 with higher safety compared with HF A A total 523 HF derivatives were tested for in vitro efficacy, intracellular efficacy, cytotoxicity, in vivo efficacy, and in vivo toxicity as described in the Methods section. DWN12088 was selected as the final candidate. At each step, the compounds that met each screening criteria are shown in pink lines. The detailed screening strategy is described in Fig EV2.B Dose–response curve of HF and DWN12088 in WI‐26 VA4 cells. The IC50 value for collagen level was measured as a representative of chemical efficacy. The cells were starved of serum for 6 h and then incubated with the indicated concentrations of compounds in the presence of TGF‐β (2 ng/ml) for 72 h. The secreted pro‐collagen I levels were determined by ELISA. The CC50 values were determined by CellTiter‐Glo assay. Dose–response curves were determined by combining at least two biologically independent experiments. The IC50 values were calculated using GraphPad Prism 7.0 (Collagen level, n = 5 from three independent experiments (singlicate for one experiment and duplicate for two experiments; mean ± SEM); Celltiter‐Glo assay, n = 4 from two independent experiments (duplicate for each experiment; mean ± SEM).C The TI of HF and DWN12088 was determined by dividing the CC50 with the IC50 for collagen level (Welch's t test; ***P < 0.001; mean ± SEM).D Schedules of two different in vivo efficacy tests.E–I In vivo efficacy of HF and DWN12088 was determined in a bleomycin‐induced lung fibrosis model. The indicated concentrations of HF or DWN12088 were orally administered to mice once a day for 2 weeks from a week after intratracheal injection of bleomycin (D, model 1). The saturation of percutaneous oxygen (SpO2) (E) was determined as a measurement of lung function. The number of cells in bronchoalveolar lavage fluid (BALF) was counted as a measure of inflammation response (F). The collagen level was determined by hydroxyproline assay (G) and Masson's trichrome staining (H and I) of lung tissues. The remaining Masson's trichrome staining images shown in Fig 1I are presented in Appendix Fig S2 (n = 5; Mann–Whitney test after Kruskal–Wallis test; *P < 0.05, **P < 0.01; mean ± SEM). scale bar = 200 μm. BLM, bleomycin; PO, per oral; QD, once a day; 12088, DWN12088; HF (0.05), HF 0.05 mg/kg; HF (0.1), HF 0.1 mg/kg; DWN12088 (10), DWN12088 10 mg/kg; b, bronchiole; v, blood vessel. Source data are available online for this figure.CC BY · PubMed Central
Figure EV2 Screening workflow and selection criteria of HF derivatives A Strategy used in screening for HF derivatives. In total, 523 synthesized compounds were tested for their efficacy in inhibiting the catalytic activity of PARS1 in vitro. Among them, 92 compounds which could inhibit PARS1 activity by more than 80% at 1 μM were further examined to obtain their IC50 values. Twenty‐eight compounds that showed IC50 values lower than 100 nM were tested for their efficacy to reduce collagen in cell. Among them, 13 compounds that suppressed collagen levels by more than 50% at 1 μM were tested at multiple doses and 8 compounds showing IC50 values lower than 400 nM were tested for cytotoxicity. By comparing the IC50 values of collagen levels to the CC50 values, two compounds were selected and further tested in in vivo efficacy and in vivo toxicity models. DWN12088 was finally selected by considering both its efficacy and toxicity doses in vivo.B Heat‐map of the inhibitory activities of 523 DWN compounds in in vitro prolylation assay at 1 μM.C Heat‐map of the inhibitory activities of 28 DWN compounds to collagen levels in 3D cell culture at 1 μM.D IC50 values for collagen level in 3D cell culture and CC50 values of eight compounds were listed in the table. The ratio of CC50 to collagen IC50 was calculated to estimate TI.E–H In vivo Efficacy of DWN compounds was determined in a transverse aortic constriction model. Pirfenidone was used as a positive control for anti‐fibrotic effect. The thickness of left ventricle (E), percentage of perivascular (F) and interstitial (G) collagen fiber, and number of infiltrated inflammatory cells (H) were determined as a measurement of fibrosis. DWN compounds and pirfenidone were administered at 10 mg/kg/day and 200 mg/kg/day, respectively (n = 10; One‐way ANOVA; ***P < 0.001; mean ± SEM).I In vivo toxicity of DWN10290 was determined in 2‐week repeated dose toxicity study. HDW, hemoglobin concentration distribution width; RDW, red cell distribution width; MPV, mean platelet volume; MONO, monocyte; HGB, hemoglobin concentration; HCT, hematocrit; MCH, mean cell hemoglobin; MCHC, mean cell hemoglobin concentration; RBC, red blood cell; WBC, white blood cell; LYMP, lymphocyte; TBIL, total bilirubin; ALP, alkaline phosphatase; TG, triglyceride; HDL, high density lipoprotein; LDL, low density lipoprotein; CHO, cholesterol; BUN, blood urea nitrogen. Source data are available online for this figure.
Figure EV2 Screening workflow and selection criteria of HF derivatives A Strategy used in screening for HF derivatives. In total, 523 synthesized compounds were tested for their efficacy in inhibiting the catalytic activity of PARS1 in vitro. Among them, 92 compounds which could inhibit PARS1 activity by more than 80% at 1 μM were further examined to obtain their IC50 values. Twenty‐eight compounds that showed IC50 values lower than 100 nM were tested for their efficacy to reduce collagen in cell. Among them, 13 compounds that suppressed collagen levels by more than 50% at 1 μM were tested at multiple doses and 8 compounds showing IC50 values lower than 400 nM were tested for cytotoxicity. By comparing the IC50 values of collagen levels to the CC50 values, two compounds were selected and further tested in in vivo efficacy and in vivo toxicity models. DWN12088 was finally selected by considering both its efficacy and toxicity doses in vivo.B Heat‐map of the inhibitory activities of 523 DWN compounds in in vitro prolylation assay at 1 μM.C Heat‐map of the inhibitory activities of 28 DWN compounds to collagen levels in 3D cell culture at 1 μM.D IC50 values for collagen level in 3D cell culture and CC50 values of eight compounds were listed in the table. The ratio of CC50 to collagen IC50 was calculated to estimate TI.E–H In vivo Efficacy of DWN compounds was determined in a transverse aortic constriction model. Pirfenidone was used as a positive control for anti‐fibrotic effect. The thickness of left ventricle (E), percentage of perivascular (F) and interstitial (G) collagen fiber, and number of infiltrated inflammatory cells (H) were determined as a measurement of fibrosis. DWN compounds and pirfenidone were administered at 10 mg/kg/day and 200 mg/kg/day, respectively (n = 10; One‐way ANOVA; ***P < 0.001; mean ± SEM).I In vivo toxicity of DWN10290 was determined in 2‐week repeated dose toxicity study. HDW, hemoglobin concentration distribution width; RDW, red cell distribution width; MPV, mean platelet volume; MONO, monocyte; HGB, hemoglobin concentration; HCT, hematocrit; MCH, mean cell hemoglobin; MCHC, mean cell hemoglobin concentration; RBC, red blood cell; WBC, white blood cell; LYMP, lymphocyte; TBIL, total bilirubin; ALP, alkaline phosphatase; TG, triglyceride; HDL, high density lipoprotein; LDL, low density lipoprotein; CHO, cholesterol; BUN, blood urea nitrogen. Source data are available online for this figure.CC BY · PubMed Central
Figure EV3 Kinetic and binding properties of HF and DWN12088 A–E The inhibitory activities of HF and DWN12088 were monitored by determining the catalytic activities of PARS1 under the indicated concentrations of proline and ATP. The IC50 values and slopes are listed in the table (A (HF), n = 5 from two independent experiments (triplicate for one experiment and duplicate for one experiment); A (DWN12088), n = 7 from three independent experiments (triplicate for one experiment and duplicate for two experiments); (B–D) technical replicate n = 3; (E) n = 9 from three independent experiments (triplicate for each experiment); mean ± SEM).F, G IC50 values of HF and DWN12088 for in vitro prolylation assay were listed in the tables.H The interaction of PARS1 and the indicated compounds in the presence or absence of ATP was determined via SPR. Affinity (KD) of the compound to PARS1 is shown on the top of the sensorgram. Source data are available online for this figure.
Figure EV3 Kinetic and binding properties of HF and DWN12088 A–E The inhibitory activities of HF and DWN12088 were monitored by determining the catalytic activities of PARS1 under the indicated concentrations of proline and ATP. The IC50 values and slopes are listed in the table (A (HF), n = 5 from two independent experiments (triplicate for one experiment and duplicate for one experiment); A (DWN12088), n = 7 from three independent experiments (triplicate for one experiment and duplicate for two experiments); (B–D) technical replicate n = 3; (E) n = 9 from three independent experiments (triplicate for each experiment); mean ± SEM).F, G IC50 values of HF and DWN12088 for in vitro prolylation assay were listed in the tables.H The interaction of PARS1 and the indicated compounds in the presence or absence of ATP was determined via SPR. Affinity (KD) of the compound to PARS1 is shown on the top of the sensorgram. Source data are available online for this figure.CC BY · PubMed Central
Figure EV4 In vivo efficacy of DWN12088 A–C The in vivo efficacy of DWN12088 was determined in a BLM‐induced lung fibrosis model. The indicated compounds were administered a day before oropharyngeal administration of BLM. DWN12088 was administered at 3, 10, 30 mg/kg once a day and pirfenidone was administered at 100 mg/kg twice a day (200 mg/kg per day). After administering the compounds for 3 weeks, modified Ashcroft score (A) (Hubner et al, 2008), lung weight (B), and collagen content in BALF (C) were determined (n = 10; Mann–Whitney test after Kruskal–Wallis test; *P < 0.05, **P < 0.01; mean ± SEM). BLM, bleomycin; Pir, pirfenidone; NS, not significant.D–F The in vivo efficacy of DWN12088, nintedanib and pirfenidone was compared in a BLM‐induced lung fibrosis model. DWN12088 10 mg/kg, nintedanib 60 mg/kg and pirfenidone 200 mg/kg were orally administered to mice once a day from a week after intratracheal injection of BLM. After administering the compounds for 2 weeks, SpO2 (D), BALF total cell count (E) and collagen contents (F) were determined (n = 9; Mann–Whitney test after Kruskal–Wallis test; *P < 0.05, **P < 0.01, ***P < 0.001; mean ± SEM). BLM, bleomycin; NS, not significant.G–I The in vivo efficacy of HF and DWN12088 was compared in a BLM‐induced lung fibrosis model. HF (0.05 and 0.1 mg/kg), and DWN12088 (10 mg/kg) were orally administered to mice once a day from 2 weeks after intratracheal injection of BLM. After administering for 2 weeks, SpO2 (G), BALF total cell count (H), collagen contents (I) were determined (n = 9; Mann–Whitney test after Kruskal–Wallis test; mean ± SEM). BLM, bleomycin; 12088, DWN12088. Source data are available online for this figure.
Figure EV4 In vivo efficacy of DWN12088 A–C The in vivo efficacy of DWN12088 was determined in a BLM‐induced lung fibrosis model. The indicated compounds were administered a day before oropharyngeal administration of BLM. DWN12088 was administered at 3, 10, 30 mg/kg once a day and pirfenidone was administered at 100 mg/kg twice a day (200 mg/kg per day). After administering the compounds for 3 weeks, modified Ashcroft score (A) (Hubner et al, 2008), lung weight (B), and collagen content in BALF (C) were determined (n = 10; Mann–Whitney test after Kruskal–Wallis test; *P < 0.05, **P < 0.01; mean ± SEM). BLM, bleomycin; Pir, pirfenidone; NS, not significant.D–F The in vivo efficacy of DWN12088, nintedanib and pirfenidone was compared in a BLM‐induced lung fibrosis model. DWN12088 10 mg/kg, nintedanib 60 mg/kg and pirfenidone 200 mg/kg were orally administered to mice once a day from a week after intratracheal injection of BLM. After administering the compounds for 2 weeks, SpO2 (D), BALF total cell count (E) and collagen contents (F) were determined (n = 9; Mann–Whitney test after Kruskal–Wallis test; *P < 0.05, **P < 0.01, ***P < 0.001; mean ± SEM). BLM, bleomycin; NS, not significant.G–I The in vivo efficacy of HF and DWN12088 was compared in a BLM‐induced lung fibrosis model. HF (0.05 and 0.1 mg/kg), and DWN12088 (10 mg/kg) were orally administered to mice once a day from 2 weeks after intratracheal injection of BLM. After administering for 2 weeks, SpO2 (G), BALF total cell count (H), collagen contents (I) were determined (n = 9; Mann–Whitney test after Kruskal–Wallis test; mean ± SEM). BLM, bleomycin; 12088, DWN12088. Source data are available online for this figure.CC BY · PubMed Central
Figure 2 Effect of HF and DWN12088 on protein translation and TGF‐β pathway WI‐26 VA4 cells were incubated in the presence of the indicated concentrations of HF and DWN12088 for 72 h. The chemical concentrations were determined based on the IC50 for collagen level (HF, 15 nM; DWN12088, 2 μM). The levels of proteins were determined by immunoblot assay. The proline content of the proteins based on Uniprot amino acid sequence is shown on the right side of the immunoblot images.The plot of “proline percentage in the protein” versus “chemical concentration relative to IC50 for collagen” is displayed based on (A). The lowest concentration at which protein levels started to decrease was normalized by IC50 values for collagen level and used as the y‐axis value. Proteins with no change in level, such as RagC in the DWN12088‐treated group, were excluded from the plot. The slope and R2 value were calculated using GraphPad Prism 7.0. ULK1, unc‐51 like autophagy activating kinase 1; AIMP2, aminoacyl tRNA synthetase complex interacting multifunctional protein 2; AMPKα, protein kinase AMP‐activated catalytic subunit alpha; RagC, Ras‐related GTP binding C.WI‐26 VA4 cells were incubated with the indicated concentrations of HF and DWN12088 in the presence of 2 ng/ml TGF‐β for 15 h. The chemical concentrations were determined based on the IC50 values for collagen levels (HF, 15 nM; DWN12088, 2 μM). The activation of the TGF‐β pathway was determined by monitoring the phosphorylation of SMAD2. Immunoblot images are representative of three biologically independent experiments.The band intensities of the immunoblot images in (C) were quantified using ImageJ (n = 3; One‐way ANOVA; *P < 0.05, **P < 0.01, ***P < 0.001; mean ± SEM). Source data are available online for this figure.
Figure 2 Effect of HF and DWN12088 on protein translation and TGF‐β pathway WI‐26 VA4 cells were incubated in the presence of the indicated concentrations of HF and DWN12088 for 72 h. The chemical concentrations were determined based on the IC50 for collagen level (HF, 15 nM; DWN12088, 2 μM). The levels of proteins were determined by immunoblot assay. The proline content of the proteins based on Uniprot amino acid sequence is shown on the right side of the immunoblot images.The plot of “proline percentage in the protein” versus “chemical concentration relative to IC50 for collagen” is displayed based on (A). The lowest concentration at which protein levels started to decrease was normalized by IC50 values for collagen level and used as the y‐axis value. Proteins with no change in level, such as RagC in the DWN12088‐treated group, were excluded from the plot. The slope and R2 value were calculated using GraphPad Prism 7.0. ULK1, unc‐51 like autophagy activating kinase 1; AIMP2, aminoacyl tRNA synthetase complex interacting multifunctional protein 2; AMPKα, protein kinase AMP‐activated catalytic subunit alpha; RagC, Ras‐related GTP binding C.WI‐26 VA4 cells were incubated with the indicated concentrations of HF and DWN12088 in the presence of 2 ng/ml TGF‐β for 15 h. The chemical concentrations were determined based on the IC50 values for collagen levels (HF, 15 nM; DWN12088, 2 μM). The activation of the TGF‐β pathway was determined by monitoring the phosphorylation of SMAD2. Immunoblot images are representative of three biologically independent experiments.The band intensities of the immunoblot images in (C) were quantified using ImageJ (n = 3; One‐way ANOVA; *P < 0.05, **P < 0.01, ***P < 0.001; mean ± SEM). Source data are available online for this figure.CC BY · PubMed Central
Figure 3 Comparison of HF and DWN compounds in the PARS1 binding mode A, B Overall structures of PARS1 complexed with the indicated compounds. PARS1 shows two types of the compound‐binding states (rigid and loose binding). PARS1 chains with rigid binding are displayed in gray and blue, whereas those with loose binding are displayed in pink. ATP is designated as green, and the compounds are designated as magenta stick models. R‐loop (K1091 – F1097) and A‐loop (R1152 – R1165) are presented as orange and yellow, respectively. The disordered region of R‐loop is presented as orange dashed lines.C Superposition of PARS1 protomers A and B of DWN compound‐ and HF‐bound structures at the residues important for the interaction with the compounds and ATP. Structures of protomer A are represented as transparent gray stick models. The color code of the structures is the same as that shown in Fig 3A and B. Source data are available online for this figure.
Figure 3 Comparison of HF and DWN compounds in the PARS1 binding mode A, B Overall structures of PARS1 complexed with the indicated compounds. PARS1 shows two types of the compound‐binding states (rigid and loose binding). PARS1 chains with rigid binding are displayed in gray and blue, whereas those with loose binding are displayed in pink. ATP is designated as green, and the compounds are designated as magenta stick models. R‐loop (K1091 – F1097) and A‐loop (R1152 – R1165) are presented as orange and yellow, respectively. The disordered region of R‐loop is presented as orange dashed lines.C Superposition of PARS1 protomers A and B of DWN compound‐ and HF‐bound structures at the residues important for the interaction with the compounds and ATP. Structures of protomer A are represented as transparent gray stick models. The color code of the structures is the same as that shown in Fig 3A and B. Source data are available online for this figure.CC BY · PubMed Central
Figure EV5 The crystal structures of PARS1 complexed with DWN compounds A–C Overall structures of PARS1 complexed with the indicated compounds. PARS1 shows two types of the compound‐binding states (rigid and loose binding). PARS1 chains with rigid binding are displayed in gray and blue whereas those with loose binding are displayed in pink. ATP is designated as green, and the compounds are designated as magenta stick models. R‐loop (K1091 – F1097) and A‐loop (R1152 – R1165) are presented as orange and yellow, respectively. The disordered region of R‐loop is presented as orange dashed lines.D Superposition of structures bound to DWN compounds and HF at the residues important for the interaction with compounds and ATP. DWN compound‐bound structures are superposed with the F1097, R1152, E1154 and R1163 of 4HVC, which are represented as transparent gray stick models. The color codes of the structures are the same as those used in Fig 3A and B.
Figure EV5 The crystal structures of PARS1 complexed with DWN compounds A–C Overall structures of PARS1 complexed with the indicated compounds. PARS1 shows two types of the compound‐binding states (rigid and loose binding). PARS1 chains with rigid binding are displayed in gray and blue whereas those with loose binding are displayed in pink. ATP is designated as green, and the compounds are designated as magenta stick models. R‐loop (K1091 – F1097) and A‐loop (R1152 – R1165) are presented as orange and yellow, respectively. The disordered region of R‐loop is presented as orange dashed lines.D Superposition of structures bound to DWN compounds and HF at the residues important for the interaction with compounds and ATP. DWN compound‐bound structures are superposed with the F1097, R1152, E1154 and R1163 of 4HVC, which are represented as transparent gray stick models. The color codes of the structures are the same as those used in Fig 3A and B.CC BY · PubMed Central
Figure 4 Detailed PARS1 binding modes of HF and DWN compounds Zoomed view of the compound binding site and its surrounding. The 2Fo – Fc map of compounds and the loop are shown as mesh model at a 2.0‐sigma (blue mesh) and 1.5‐sigma contour level (green mesh, R‐loop; brown mesh, A‐loop), respectively.Detailed binding mode of HF and DWN compounds. The color scheme of PARS1 is identical to that used in Fig 3A and B. Water molecules and Mg2+ ion are represented as red and green spheres, respectively. The residues that interact with ATP and compounds are represented as stick models. Hydrogen bond network is represented as black dotted lines. The number of hydrogen bonds between compounds or ATP and the residues of the A‐loop is shown at the bottom right side of the image.
Figure 4 Detailed PARS1 binding modes of HF and DWN compounds Zoomed view of the compound binding site and its surrounding. The 2Fo – Fc map of compounds and the loop are shown as mesh model at a 2.0‐sigma (blue mesh) and 1.5‐sigma contour level (green mesh, R‐loop; brown mesh, A‐loop), respectively.Detailed binding mode of HF and DWN compounds. The color scheme of PARS1 is identical to that used in Fig 3A and B. Water molecules and Mg2+ ion are represented as red and green spheres, respectively. The residues that interact with ATP and compounds are represented as stick models. Hydrogen bond network is represented as black dotted lines. The number of hydrogen bonds between compounds or ATP and the residues of the A‐loop is shown at the bottom right side of the image.CC BY · PubMed Central
Figure 5 Comparative analysis of HF and DWN compounds for their efficacy and toxicity A The IC50 values of the indicated compounds were determined for collagen level as described in Methods section (HF and DWN12088, n = 8 from four independent experiments (duplicate for each experiment); DWN11748, n = 12 from six independent experiments (duplicate for each experiment); DWN11761 and DWN11251, n = 6 from three independent experiments (duplicate for each experiment); mean ± SEM).B The IC50 values of the indicated compounds were determined for cytotoxicity (CC50) as described in Methods section (n = 4 from two independent experiments (duplicate for each experiment); mean ± SEM).C The IC50 values of the indicated compounds were determined for TNT‐luciferase activity as described in Methods section (n = 6 from two independent experiments (triplicate for each experiment); only for DWN11761, n = 9 from three independent experiments (triplicate for each experiment); mean ± SEM).D The IC50 values of the indicated compounds were determined for puromycin incorporation as described in Methods section (HF, n = 12 from four independent experiments (triplicate for each experiment); DWN11748, DWN12088, and DWN11251, n = 9 from three independent experiments (triplicate for each experiment); DWN11761, n = 8 from three independent experiments (triplicate for two experiments and duplicate for one experiment); mean ± SEM).E–G Relative ratio of CC50 (E), TNT‐luciferase activity IC50 (F) and puromycin incorporation IC50 (G) to the IC50 of collagen levels shown in (A) was calculated (mean ± SEM). IC50 values were determined by using Graph Pad Prim 7.0.H–J Relative slopes of the dose–response curves shown in (A, C and D) were calculated using GraphPad Prism 7.0 (Welch's t test; *P < 0.05, **P < 0.01, ***P < 0.001; mean ± SEM). Source data are available online for this figure.
Figure 5 Comparative analysis of HF and DWN compounds for their efficacy and toxicity A The IC50 values of the indicated compounds were determined for collagen level as described in Methods section (HF and DWN12088, n = 8 from four independent experiments (duplicate for each experiment); DWN11748, n = 12 from six independent experiments (duplicate for each experiment); DWN11761 and DWN11251, n = 6 from three independent experiments (duplicate for each experiment); mean ± SEM).B The IC50 values of the indicated compounds were determined for cytotoxicity (CC50) as described in Methods section (n = 4 from two independent experiments (duplicate for each experiment); mean ± SEM).C The IC50 values of the indicated compounds were determined for TNT‐luciferase activity as described in Methods section (n = 6 from two independent experiments (triplicate for each experiment); only for DWN11761, n = 9 from three independent experiments (triplicate for each experiment); mean ± SEM).D The IC50 values of the indicated compounds were determined for puromycin incorporation as described in Methods section (HF, n = 12 from four independent experiments (triplicate for each experiment); DWN11748, DWN12088, and DWN11251, n = 9 from three independent experiments (triplicate for each experiment); DWN11761, n = 8 from three independent experiments (triplicate for two experiments and duplicate for one experiment); mean ± SEM).E–G Relative ratio of CC50 (E), TNT‐luciferase activity IC50 (F) and puromycin incorporation IC50 (G) to the IC50 of collagen levels shown in (A) was calculated (mean ± SEM). IC50 values were determined by using Graph Pad Prim 7.0.H–J Relative slopes of the dose–response curves shown in (A, C and D) were calculated using GraphPad Prism 7.0 (Welch's t test; *P < 0.05, **P < 0.01, ***P < 0.001; mean ± SEM). Source data are available online for this figure.CC BY · PubMed Central
Figure 6 Effect of PARS1 dimeric interaction on the efficacy and toxicity of HF and DWN12088 A The role of F1097, E1123 and R1152 in the binding to the compounds, ATP and proline in complex structures of PARS1‐HF‐ANP (PDB: 4HVC), PARS1‐DWN12088‐ATP and PARS1‐proline (PDB: 4K87). The color codes of the structures are the same as those shown in Fig 3A and B.B The binding of HF and DWN12088 to in vitro purified PARS1 WT and F1097A/E1123A/R1152L (FA/EA/RL) mutant was determined via microscale thermophoresis (MST). Kd values are listed in the top left part of the graph (technical replicates n = 3; mean ± SD).C Catalytic activities of PARS1 WT and FA/EA/RL mutant were determined by prolylation assay in the presence of [3H]proline. To monitor the effect of PARS1 RA/EA/RL mutant on the activity of PARS1 WT, the same concentrations of the proteins were pre‐incubated for 10 min and then used for the assay. The formation of Pro‐tRNAPro was measured using liquid scintillation counter (technical replicates n = 3; mean ± SEM).D The kinetic values of PARS1 with homodimer (WT/WT) and heterodimer (WT/MT) settings were determined by prolylation assay in the presence of [3H]proline. MT, PARS1 FA/EA/RL (biological replicates n ≥ 3; mean ± SEM).E 293 T cells were transfected with the indicated plasmid DNAs for 24 h. The cell lysates were prepared and pulled down with Strep bead for 2 h. Co‐precipitated proteins were determined by immunoblot assay. WT, PARS1 wild type; MT, PARS1 FA/EA/RL.F Schematic representation of the strategy for generating a monomer‐like EPRS1. Endogenous EPRS1 dimer would function as a monomer‐like EPRS1 by forming a dimer with exogenous PARS1 mutant that cannot bind to the compounds and does not show the catalytic activity.G, H WI‐26 VA4 cells stably expressing each of EV (empty vector) or PARS1 FA/EA/RL mutant were incubated with the indicated compounds for 72 h. Dose–response curves of the compounds for collagen levels and cytotoxicity were determined and relative ratio of CC50 to the IC50 of collagen for HF (G) and DWN12088 (H) were calculated. The IC50 values were calculated using GraphPad Prism 7.0 (collagen ELISA, n = 12 from four independent experiments (triplicate for each experiment); cytotoxicity assay, n = 8 from four independent experiments (duplicate for each experiment); Welch's t test; ***P < 0.001; mean ± SEM).I, J Relative slopes of dose–response curves of HF (I) and DWN12088 (J) for collagen levels were determined in cells stably expressing each of EV or PARS1 FA/EA/RL mutant. The slopes were determined by using GraphPad Prism 7.0 (n = 3 in triplicates for collagen ELISA, n = 4 in duplicates for cytotoxicity assay; mean ± SEM; Welch's t test; ***P < 0.001; mean ± SEM).K WI‐26 VA4 cells stably expressing each of EV or PARS1 FA/EA/RL mutant were incubated with the indicated compounds in the presence of TGF‐β for 72 h. The levels of the indicated proteins were determined by immunoblotting. The percentage of proline in polypeptide sequences is shown on the right side of immunoblot images. Source data are available online for this figure.
Figure 6 Effect of PARS1 dimeric interaction on the efficacy and toxicity of HF and DWN12088 A The role of F1097, E1123 and R1152 in the binding to the compounds, ATP and proline in complex structures of PARS1‐HF‐ANP (PDB: 4HVC), PARS1‐DWN12088‐ATP and PARS1‐proline (PDB: 4K87). The color codes of the structures are the same as those shown in Fig 3A and B.B The binding of HF and DWN12088 to in vitro purified PARS1 WT and F1097A/E1123A/R1152L (FA/EA/RL) mutant was determined via microscale thermophoresis (MST). Kd values are listed in the top left part of the graph (technical replicates n = 3; mean ± SD).C Catalytic activities of PARS1 WT and FA/EA/RL mutant were determined by prolylation assay in the presence of [3H]proline. To monitor the effect of PARS1 RA/EA/RL mutant on the activity of PARS1 WT, the same concentrations of the proteins were pre‐incubated for 10 min and then used for the assay. The formation of Pro‐tRNAPro was measured using liquid scintillation counter (technical replicates n = 3; mean ± SEM).D The kinetic values of PARS1 with homodimer (WT/WT) and heterodimer (WT/MT) settings were determined by prolylation assay in the presence of [3H]proline. MT, PARS1 FA/EA/RL (biological replicates n ≥ 3; mean ± SEM).E 293 T cells were transfected with the indicated plasmid DNAs for 24 h. The cell lysates were prepared and pulled down with Strep bead for 2 h. Co‐precipitated proteins were determined by immunoblot assay. WT, PARS1 wild type; MT, PARS1 FA/EA/RL.F Schematic representation of the strategy for generating a monomer‐like EPRS1. Endogenous EPRS1 dimer would function as a monomer‐like EPRS1 by forming a dimer with exogenous PARS1 mutant that cannot bind to the compounds and does not show the catalytic activity.G, H WI‐26 VA4 cells stably expressing each of EV (empty vector) or PARS1 FA/EA/RL mutant were incubated with the indicated compounds for 72 h. Dose–response curves of the compounds for collagen levels and cytotoxicity were determined and relative ratio of CC50 to the IC50 of collagen for HF (G) and DWN12088 (H) were calculated. The IC50 values were calculated using GraphPad Prism 7.0 (collagen ELISA, n = 12 from four independent experiments (triplicate for each experiment); cytotoxicity assay, n = 8 from four independent experiments (duplicate for each experiment); Welch's t test; ***P < 0.001; mean ± SEM).I, J Relative slopes of dose–response curves of HF (I) and DWN12088 (J) for collagen levels were determined in cells stably expressing each of EV or PARS1 FA/EA/RL mutant. The slopes were determined by using GraphPad Prism 7.0 (n = 3 in triplicates for collagen ELISA, n = 4 in duplicates for cytotoxicity assay; mean ± SEM; Welch's t test; ***P < 0.001; mean ± SEM).K WI‐26 VA4 cells stably expressing each of EV or PARS1 FA/EA/RL mutant were incubated with the indicated compounds in the presence of TGF‐β for 72 h. The levels of the indicated proteins were determined by immunoblotting. The percentage of proline in polypeptide sequences is shown on the right side of immunoblot images. Source data are available online for this figure.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists are queued

They are fetched later and appear here then.

References 58 · Cited by 22

Metadata

Authors
Yoon, I., Kim, S., Cho, M., You, K. A., Son, J., Lee, C., Suh, J. H., Bae, D., Kim, J. M., Oh, S., Park, S., Kim, S., Cho, S. H., Park, S., Bang, K., Seo, M., Kim, J. H., Lee, B., Park, J. S., Hwang, K. Y., & Kim, S.
Affiliations
  • Yonsei University (KR)
  • Daewoong Pharmaceutical (South Korea) (KR)
  • Korea University (KR)
Corresponding author
Hwang, Kwang Yeon
Venue
EMBO Molecular Medicine
Published
2023-05-22
Volume
15
Issue
7
Pages
e16940-e16940
ISSN
  • 1757-4676 (ISSN-L)
  • 1757-4684
OpenAlex
W4377220482
Cited by
22
References
58
Citations by year
2026: 7 · 2025: 7 · 2024: 5 · 2023: 3
FWCI
1.94
Type
journal article
Language
en
Open access
Licence
Locations
  • EMBO Molecular Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Korea Drug Development Fund (KDDF‐201812‐20)
  • Ministry of Science and ICT, South Korea (2021R1A3B1076605, 2020R1A2C2005670, 2021R1C1C1013332)
  • Yonsei University (2020‐22‐0358, 2020‐22‐0356, 2021‐22‐0061)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
Keywords
idiopathic pulmonary fibrosis, fibrosis, collagen deposition, drug safety, homodimerization, protein synthesis
MeSH terms
Amino Acyl-tRNA Synthetases, Fibrosis, Humans, Proline, Protein Biosynthesis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Control of fibrosis with enhanced safety via asymmetric inhibition of prolyl‐tRNA synthetase 1. https://app.cochat.ai/papers/10.15252/emmm.202216940
The paper
Yoon, I., Kim, S., Cho, M., You, K. A., Son, J., Lee, C., Suh, J. H., Bae, D., Kim, J. M., Oh, S., Park, S., Kim, S., Cho, S. H., Park, S., Bang, K., Seo, M., Kim, J. H., Lee, B., Park, J. S., . . . Kim, S. (2023). Control of fibrosis with enhanced safety via asymmetric inhibition of prolyl‐tRNA synthetase 1. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.202216940

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.